Volume : 11, Issue : 04, April – 2024
Title:
A REVIEW ON PREPARATION OFDRUG MASTER FILE FOR REGULATORY APPROVALS
Authors :
Tadiboina Uma Maheswari*, Adilakshmi Challa, M. V. Nagabhushanam, Bolimoni Lakshmi Sravani, Yarramsetty Naga Pavani, G Ramakrishna,
Abstract :
A drug master file (DMF) is a confidential, detailed document submitted by Active Pharmaceutical Ingredient (API) manufacturers to the U.S. Food and Drug Administration (FDA). A DMF contains the chemistry, manufacturing, and controls of a drug component. A drug master file is filed when two or more firms work in partnership on developing or manufacturing a drug product. The DMF filing allows a firm to protect its intellectual property from its partner while complying with regulatory requirements for disclosure of processing details. The DMF contains factual and complete information on a drug product’s chemistry, manufacture, stability, purity, impurity profile, packaging, and the cGMP status of any human drug product. The pharmaceutical industry is one of the most regulated industries; no drug would be marketed without the teams of medical researchers and other specialists who worked to make sure it receives regulatory authority’s approval. There is no legal or regulatory requirement to file a DMF. This study gives the information on regulatory requirements of Drug Master Files by Food and Drug Administration (USA), European Medicines Agency (Europe), Ministry of Health Labor and Welfare (Japan), Central Drug and Standard Control Organization (India) and WHO and their comparison.
Keywords: DMF, intellectual property, regulatory authority, FDA, WHO.
Cite This Article:
Please cite this article in press Tadiboina Uma Maheswari et al, A Review On Preparation Of drug Master File For Regulatory Approvals.,Indo Am. J. P. Sci, 2024; 11 (4).
Number of Downloads : 10
References:
1. https://www.fda.gov
2. https://www.pmda.go.ja
3. https://www.pharmaguideline.com
4. https://freyersolutions.com
5. https://regulatoryaffairs.freyersolutions.com
6. .https://www.pcisynthesis.com
7. https://www.ema.europa.eu
8. https://en.wikipedia.org/wiki/Drug_Master_File
9. https://www.fdahelp.us/drug-master-files.html
10. https://www.hsa.gov.sg/therapeutic-products/register/guides/drug-master-file
11. Brahmaiah Bonthagarala, Regulatory Requirements for Registration of Generic Drugs in “BRICS” Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 20-39.
12. Brahmaiah Bonthagarala, Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic Goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, Issue 6 volume 6, November-December 2016, 144-157.
13. Brahmaiah Bonthagarala, Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 1-19.
14. Brahmaiah Bonthagarala, Nanomedicine Clinical Use, Regulatory and Toxicology Issues in Europe, Journal of Drug Delivery and Therapeutics, 2019; 9(4-s):846-848.
15. Brahmaiah Bonthagarala,Generic Drug Registration and Regulatory Requirements in European Countries,World Journal of Pharmaceutical Research, 2018, Volume 7, Issue 16, 800-815.
16. KumarB.ComparisonofRegulatoryRequirementsforGenericDrugsDossierInUnitedStatesAndEurope.JournalofPharmaResearch.2019;8(8).